ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment Genzyme, 31 Mar 2009 Accessed on 6 Dec 2011 from http://www.genzyme.com/corp/media/GENZ%20PR-033109.asp.
Monoclonal antibodies in MS: mechanisms of action. Bielekova B, Becker BL Neurology. 2010 Jan 5; 74 Suppl 1:S31-40. PMID: 20038761. Abstract
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Klotz L, Meuth SG, Wiendl H Clin Immunol. 2012 Jan; 142(1):25-30. Epub 2011 Apr 15. PMID: 21550857. Abstract
European Medicines Agency, Scientific Discussion of MabCampath (alemtuzumab) European Medicines Agency, 2005 Accessed on 6 Dec 2011 from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000353/WC500025264.pdf.
Food and Drug Administration drug insert for Campath (alemtuzumab) Food and Drug Administration, Sep 2007 Accessed on 7 Dec 2011 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103948s5070lbl.pdf.
Alemtuzumab DrugBank, Open Data Drug & Drug Target Database Accessed on 6 Dec 2011 from http://www.drugbank.ca/drugs/DB00087.
Alemtuzumab and multiple sclerosis: therapeutic application. Minagar A, Alexander SJ, Sahraian M A, Zivadinov R Expert Opin Biol Ther. 2010 Mar; 10(3):421-9. PMID: 20095876. Abstract
Pharmacokinetics of CAMPATH-1H in BMT patients. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G Cytotherapy. 2001; 3(4):261-7. PMID: 12171714. Abstract
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, Moreton P, et al. Blood. 2004 Aug 15; 104(4):948-55. Epub 2004 Apr 15. PMID: 15090452. Abstract
Alemtuzumab for the Treatment of Multiple Sclerosis Tom Button and Alasdair Coles, Future Neurology 5:177-188, 2010 Accessed on 6 Dec 2011 from http://www.medscape.com/viewarticle/718543. Note: Free password required
Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Buttmann M Expert Rev Neurother. 2010 May; 10(5):791-809. PMID: 20420497. Abstract
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Jones JL, Anderson JM, Phuah C-L, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, et al. Brain. 2010 Aug; 133(Pt 8):2232-47. Epub 2010 Jul 21. PMID: 20659956. Abstract
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis Genzyme, 11 Jul 2011 Accessed on 6 Dec 2011 from http://www.businesswire.com/news/genzyme/20110710005114/en.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. CAMMS223 Trial Investigators, Coles AJ, Compston ADS, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK N Engl J Med. 2008 Oct 23; 359(17):1786-801. PMID: 18946064. Abstract
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass A D-D, Wynn DR, Margolin DH, Lake SL, et al. Lancet Neurol. 2011 Apr; 10(4):338-48. PMID: 21397567. Abstract
Food and Drug Administration Approval Letter for Alemtuzumab Food and Drug Administation, 7 May 2001 Accessed on 7 Dec 2011 from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088605.pdf.
European Medicines Agency European Medicines Agency Accessed on 7 Dec 2011 from http://www.ema.europa.eu. Note: "search term: alemtuzumab"
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Agarwal A, Shen LY, Kirk AD Transpl Immunol. 2008 Nov; 20(1-2):6-11. Epub 2008 Sep 29. PMID: 18824230. Abstract
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab. Selleri C, Serio B, Risitano AM Mini Rev Med Chem. 2011 Jun; 11(6):536-43. PMID: 21561402. Abstract
National Cancer Institute Search for Clinical Trials National Cancer Institute Accessed on 7 Dec 2011 from http://www.cancer.gov/clinicaltrials/search. Note: Search term: "alemtuzumab"
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). Jones JL, Phuah C-L, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ J Clin Invest. 2009 Jul; 119(7):2052-61. Epub 2009 Jun 22. PMID: 19546505. Abstract
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. Thompson SAJ, Jones JL, Cox AL, Compston ADS, Coles AJ J Clin Immunol. 2010 Jan; 30(1):99-105. Epub 2009 Sep 10. PMID: 19763798. Abstract
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease Genzyme, 10 Apr 2010 Accessed on 6 Dec 2011 from http://www.businesswire.com/news/genzyme/20100414005228/en.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Coles A, Deans J, Compston A Clin Neurol Neurosurg. 2004 Jun; 106(3):270-4. PMID: 15177782. Abstract
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA TM*) in Multiple Sclerosis Sanofi, 11 Nov 2011 Accessed on 7 Dec 2011 from http://en.sanofi.com/Images/29137_20111114_CARE_en.pdf.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis Business Wire, 12 Jun 2012 Accessed on 8 Aug 2012 from http://www.businesswire.com/news/genzyme/20120611006439/en.
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj K, Skoromets A, Stolyarov I, Bass A, Sullivan H, et al. Neurology. 2012 Apr 3; 78(14):1069-78. Epub 2012 Mar 21. PMID: 22442431. Abstract
Genzyme provides update on U.S. LEMTRADA™ filing Genzyme, 27 Aug 2012 Accessed on 27 Aug 2012 from http://www.businesswire.com/news/genzyme/20120826005056/en.
Sanofi withdraws Campath in US and EU PharmaTimes, 21 Aug 2012 Accessed on 27 Aug 2012 from http://www.pharmatimes.com/Article/12-08-21/Sanofi_withdraws_Campath_in_US_and_EU.aspx.
Editors' Pick Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, et al. Lancet. 2012 Oct 31. PMID: 23122652. Abstract
Editors' Pick Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, et al. Lancet. 2012 Oct 31. PMID: 23122650. Abstract
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. Perumal JS, Foo F, Cook P, Khan O Mult Scler. 2012 Aug; 18(8):1197-9. Epub 2012 Jan 17. PMID: 22252465. Abstract
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston ADS, Fahey MT, et al. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):298-304. Epub 2011 Nov 05. PMID: 22056965. Abstract
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Fox EJ, Sullivan HC, Gazda SK, Mayer L, O'Donnell L, Melia K, Lake SL Eur J Neurol. 2012 Feb; 19(2):307-11. Epub 2011 Sep 07. PMID: 21899662. Abstract
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM Immunology. 2009 Oct; 128(2):260-70. PMID: 19740383. Abstract
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Cossburn MD, Harding K, Ingram G, El-Shanawany T, Heaps A, Pickersgill TP, Jolles S, Robertson NP Neurology. 2013 Jan 1; 80(1):55-61. Epub 2012 Dec 12. PMID: 23243077. Abstract
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA Genzyme, 28 Jan 2013 Accessed on 29 Jan 2013 from http://news.genzyme.com/press-release/genzymes-lemtrada-alemtuzumab-application-ms-accepted-review-fda.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4 Reuters, 14 Feb 2013 Accessed on 18 Feb 2013 from http://www.reuters.com/article/2013/02/14/sanofi-lemtrada-idUSL5N0BEBQ720130214.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis. Graves J, Galetta SL, Palmer J, Margolin DH, Rizzo M, Bilbruck J, Balcer LJ Mult Scler. 2013 Mar 4. PMID: 23459567. Abstract
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies Genzyme, 21 Mar 2013 Accessed on 25 Mar 2013 from http://news.genzyme.com/press-release/effect-genzymes-lemtrada-maintained-patients-beyond-two-year-pivotal-ms-studies.
Company restores access to multiple sclerosis drug after pressure from neurologists. Laurance J BMJ. 2013; 346:f703. PMID: 23377614. Abstract
Alemtuzumab benefits hard-to-treat MS patients Anderson P, Medscape Today, 2 Jun 2013 Accessed on 8 Jun 2013 from http://www.medscape.com/viewarticle/805173.
Sanofi MS drug nears green light after pass-the-parcel marathon Hirschler B, Reuters, 10 Jun 2013 Accessed on 24 Jun 2013 from http://www.reuters.com/article/2013/06/10/sanofi-lemtrada-idUSL5N0EI1DC20130610.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Bandala-Sanchez E, Zhang Y, Reinwald S, Dromey JA, Lee B-H, Qian J, Böhmer RM, Harrison LC Nat Immunol. 2013 May 19; 14(7):741-8. Epub 2013 May 19. PMID: 23685786. Abstract
Immune status following alemtuzumab treatment in human CD52 transgenic mice. Turner MJ, Lamorte MJ, Chretien N, Havari E, Roberts BL, Kaplan JM, Siders WM J Neuroimmunol. 2013 Jun 4. PMID: 23759318. Abstract
Genzyme receives positive CHMP opinion for LEMTRADA™ (alemtuzumab) in Europe Genzyme, 28 Jun 2013 Accessed on 29 Jun 2013 from http://news.genzyme.com/press-release/genzyme-receives-positive-chmp-opinion-lemtrada-alemtuzumab-europe.
First use of alemtuzumab in Balo's concentric sclerosis: a case report. Brown J, Coles AJ, Jones J Mult Scler. 2013 Jul 25. PMID: 23886830. Abstract
Immune competence after alemtuzumab treatment of multiple sclerosis. McCarthy CL, Tuohy O, Compston ADS, Kumararatne DS, Coles AJ, Jones JL Neurology. 2013 Aug 7. PMID: 23925762. Abstract
European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab) Genzyme, 17 Sep 2013 Accessed on 17 Sep 2013 from http://news.genzyme.com/press-release/european-commission-approves-genzymes-multiple-sclerosis-treatment-lemtrada-alemtuzuma.
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. Balcer LJ, Galetta SL, Polman CH, Eggenberger E, Calabresi PA, Zhang A, Scanlon JV, Hyde R J Neurol Sci. 2012 Apr 20. PMID: 22521274. Abstract
Alemtuzumab 3-year data show durable effect on MS disability Hughes S, Medscape, 10 Oct 2013 Accessed on 10 Oct 2013 from http://www.medscape.com/viewarticle/812407.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Havari E, Turner MJ, Campos-Rivera J, Shankara S, Nguyenz T-H, Roberts B, Siders W, Kaplan JM Immunology. 2013 Oct 5. PMID: 24116901. Abstract
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis. Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH J Clin Endocrinol Metab. 2013 Oct 29. PMID: 24170099. Abstract
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package US Food and Drug Administration, 8 Nov 2013 Accessed on 10 Nov 2013 from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM374186.pdf.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis. Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S J Immunol. 2013 Nov 6. PMID: 24198283. Abstract
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada Zabarenko D, Reuters, 13 Nov 2013 Accessed on 20 Nov 2013 from http://www.reuters.com/article/2013/11/13/sanofi-fda-lemtrada-idUSL2N0IY26620131113.
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Jones JL, Thompson SAJ, Loh P, Davies JL, Tuohy OC, Curry AJ, Azzopardi L, Hill-Cawthorne G, Fahey MT, Compston A, et al. Proc Natl Acad Sci U S A. 2013 Dec 10; 110(50):20200-5. Epub 2013 Nov 26. PMID: 24282306. Abstract
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis Genzyme, 13 Dec 2013 Accessed on 16 Dec 2013 from http://news.genzyme.com/press-release/genzymes-lemtrada-approved-canada-treatment-multiple-sclerosis.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis Genzyme, 19 Dec 2013 Accessed on 30 Dec 2013 from http://news.genzyme.com/press-release/genzymes-lemtrada-approved-australia-treatment-multiple-sclerosis.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. Azzopardi L, Thompson SAJ, Harding KE, Cossburn M, Robertson N, Compston A, Coles AJ, Jones JL J Neurol Neurosurg Psychiatry. 2013 Dec 24. PMID: 24368840. Abstract
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application Genzyme, 30 Dec 2013 Accessed on 10 Jan 2014 from http://news.genzyme.com/press-release/genzyme-receives-complete-response-letter-fda-lemtrada-alemtuzumab-application.
Genzyme’s Lemtrada® approved in Mexico for treatment of multiple sclerosis Genzyme, 4 Feb 2014 Accessed on 13 Feb 2014 from http://news.genzyme.com/press-release/genzymes-lemtrada-approved-mexico-treatment-multiple-sclerosis.
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis Genzyme, 21 Mar 2014 Accessed on 25 Mar 2014 from http://news.genzyme.com/press-release/genzymes-lemtrada-approved-brazil-treatment-multiple-sclerosis.
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance MS Trust, 4 Apr 2014 Accessed on 4 Apr 2014 from http://www.mstrust.org.uk/news/article.jsp?id=6251.
Genzyme to Resubmit LemtradaTM Application for FDA Review Genzyme, 7 Apr 2014 Accessed on 8 Apr 2014 from http://news.genzyme.com/press-release/genzyme-resubmit-lemtradatm-application-fda-review.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM Genzyme, 30 Apr 2014 Accessed on 15 May 2014 from http://news.genzyme.com/press-release/slowing-brain-atrophy-and-reductions-new-multiple-sclerosis-lesions-sustained-three-ye.
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, et al. J Neurol Neurosurg Psychiatry. 2014 May 21. PMID: 24849515. Abstract
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Kousin-Ezewu O, Azzopardi L, Parker RA, Tuohy O, Compston A, Coles A, Jones J Neurology. 2014 May 16. PMID: 24838790. Abstract
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE) Market Watch, The Wall Street Journal, 27 May 2014 Accessed on 29 May 2014 from http://www.marketwatch.com/story/genzymes-lemtrada-recommended-for-reimbursement-on-nhs-by-the-national-institute-for-health-and-care-excellence-nice-2014-05-27.
Genzyme's Lemtrada resubmission accepted for review by FDA Genzyme, 30 May 2014 Accessed on 5 Jun 2014 from http://news.genzyme.com/press-release/genzymes-lemtrada-resubmission-accepted-review-fda.
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia. Ronchetti A-M, Henry B, Ambert-Balay K, Pothier P, Decroocq J, Leblond V, Roos-Weil D BMC Infect Dis. 2014; 14(1):239. Epub 2014 May 06. PMID: 24885918. Abstract
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis Genzyme, 30 Jun 2014 Accessed on 3 Jul 2014 from http://news.genzyme.com/press-release/genzymes-lemtrada-approved-argentina-treatment-multiple-sclerosis.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS) Market Watch, The Wall Street Journal, 7 Jul 2014 Accessed on 9 Jul 2014 from http://www.marketwatch.com/story/smc-says-yes-to-lemtradara-14-alemtuzumab-12mg-iv-a-new-treatment-for-adults-with-active-relapsing-remitting-multiple-sclerosis-rrms-2014-07-07.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. The 3C Study Collaborative Group Lancet. 2014 Jul 26. PMID: 25078310. Abstract
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies Genzyme, 11 Sep 2014 Accessed on 13 Sep 2014 from http://news.genzyme.com/press-release/four-years-treatment-effect-maintained-more-two-thirds-patients-who-received-genzymes-.
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Gelfand JM, Cotter J, Klingman J, Huang EJ, Cree BAC Neurol Neuroimmunol Neuroinflamm. 2014 Oct; 1(3):e34. Epub 2014 Oct 09. PMID: 25340086. Abstract
Genzyme’s Lemtrada Approved by the FDA Genzyme, 14 Nov 2014 Accessed on 18 Nov 2014 from http://news.genzyme.com/press-release/genzymes-lemtrada-approved-fda.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. Lepage E, Deburghgraeve V, Lester M-A, Cardiet I, Leray E, Edan G J Neurol. 2015 Feb 21. Epub 2015 Feb 21. PMID: 25701008. Abstract
Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease. Trinh T, Haridas AS, Sullivan TJ Ophthal Plast Reconstr Surg. 2015 Mar 18. PMID: 25794019. Abstract
Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study. Montalban X, Inshasi JS, Coles AJ, Hartung HP, Havrdova E, Selmaj K, Margolin DH, Palmer J, Oyuela P Mult Scler Relat Disord. 2014 Nov; 3(6):761-2. Epub 2014 Nov 21. PMID: 25891612. Abstract
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study. Kieseier BC, Sahraian MA, Coles AJ, Hartung HP, Havrdova E, Selmaj K, Margolin DH, Palmer J, Oyuela P Mult Scler Relat Disord. 2014 Nov; 3(6):756. Epub 2014 Nov 21. PMID: 25891599. Abstract
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. Malmeström C, Andersson BA, Lycke J J Neurol. 2014 Oct; 261(10):2016-8. Epub 2014 Aug 01. PMID: 25082626. Abstract
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis-Report of Two Cases. Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, Bayas A Int J Mol Sci. 2015; 16(7):14669-76. PMID: 26132570. Abstract
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis. Turner MJ, Pang PT, Chretien N, Havari E, Lamorte MJ, Oliver J, Pande N, Masterjohn E, Carter K, Reczek D, et al. J Neuroimmunol. 2015 Aug 15; 285:4-12. Epub 2015 May 20. PMID: 26198912. Abstract
Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience. Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DRW J Rheumatol. 2015 Aug 15. PMID: 26276966. Abstract
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Tramacere I, Giovane C D, Salanti G, D'Amico R, Filippini G Cochrane Database Syst Rev. 2015 Sep 18; 9:CD011381. PMID: 26384035. Abstract
Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. Isidoro L, Pires P, Rito L, Cordeiro G BMJ Case Rep. 2014; 2014. PMID: 24403383. Abstract
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials Genzyme, 8 Oct 2015 Accessed on 13 Oct 2015 from http://news.genzyme.com/press-release/treatment-effects-maintained-over-five-years-majority-patients-relapsing-remitting-mul.
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ J Neurol. 2015 Oct 17. Epub 2015 Oct 17. PMID: 26477020. Abstract
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, Smee J, Robertson NP Mult Scler. 2015 Oct 29. PMID: 26514979. Abstract
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, et al. Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e194. Epub 2016 Jan 21. PMID: 26819963. Abstract
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) ClinicalTrials.gov, 2 Nov 2015 Accessed on 17 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02419378.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. Ruck T, Afzali A M, Lukat K-F, Eveslage M, Gross CC, Pfeuffer S, Bittner S, Klotz L, Melzer N, Wiendl H, et al. BMC Neurol. 2016; 16(1):34. Epub 2016 Mar 10. PMID: 26966029. Abstract
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. Fox EJ, Wynn D, Coles AJ, Palmer J, Margolin DH, CAMMS223 Investigators J Neurol Sci. 2016 Apr 15; 363:188-94. Epub 2016 Feb 12. PMID: 27000249. Abstract
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis. Penkert H, Delbridge C, Wantia N, Wiestler B, Korn T JAMA Neurol. 2016 Apr 4. PMID: 27043129. Abstract
Ten-year follow-up shows efficacy of Sanofi's MS drug Lemtrada The Pharmaletter, 19 Apr 2016 Accessed on 18 Apr 2016 from http://www.thepharmaletter.com/article/ten-year-follow-up-shows-efficacy-of-sanofi-s-ms-drug-lemtrada.